LAG3 and myocarditis: Similarly, combined anti-PD-1/anti-LAG-3 therapy in recent trials reported somewhat higher numbers of myocarditis as compared to single anti-PD-1 therapy (1.7 vs. 0.6%, respectively) (Tawbi et al., 2022).